To date, methods of studying the effects of drugs at the molecular-genetic level are widely used in pediatric practice. The aim of our work was to evaluate the effectiveness of the effect of β2-agonists on the clinical course of recurrent bronchial obstruction (RBO) in children, depending on the variants of polymorphism of the ADRB2 gene. The effectiveness of salbutamol in children with RBO and bronchial asthma(BA) was evaluated depending on the distribution of alleles and genotypes of the ADRB2 Argl6Gly and Gln27Glu genes according to the degree of reversibility of bronchial obstruction. In the group of children with RBO carriers of the heterozygous A/G genotype of the Arg16Gly locus and the Gln27Glu locus of the ADRB2 gene, high efficacy of salbutamol therapy as a bronchodilator was noted. At the same time, in children with RBO representatives of the G/G genotype, the effectiveness of using the drug is low. In children with BA, the change in functional activity is associated with the polymorphism of the Gln27Glu gene locus and is associated with a low therapeutic response to β2–agonists in children with the G\G mutational genotype and a good effect in carriers of the homozygous variant with the A/A genotype. Knowledge of the genotype of polymorphic variants of the ADRB2 gene will make it possible to evaluate one of the factors of predisposition and effectiveness of therapy in the recurrent course of bronchial obstruction syndrome and bronchial asthma.